Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Net Margin (2016 - 2023)

Historic Net Margin for Seres Therapeutics (MCRB) over the last 8 years, with Q4 2023 value amounting to 10204.69%.

  • Seres Therapeutics' Net Margin fell 31486900.0% to 10204.69% in Q4 2023 from the same period last year, while for Sep 2025 it was 9311.11%, marking a year-over-year decrease of 848717000.0%. This contributed to the annual value of 60.48% for FY2023, which is 35699800.0% up from last year.
  • According to the latest figures from Q4 2023, Seres Therapeutics' Net Margin is 10204.69%, which was down 31486900.0% from 2206.13% recorded in Q3 2023.
  • Seres Therapeutics' Net Margin's 5-year high stood at 53.83% during Q3 2021, with a 5-year trough of 13634.87% in Q1 2023.
  • Its 5-year average for Net Margin is 2492.78%, with a median of 652.76% in 2021.
  • Over the last 5 years, Seres Therapeutics' Net Margin had its largest YoY gain of 53604100bps in 2023, and its largest YoY loss of -98422300bps in 2023.
  • Seres Therapeutics' Net Margin (Quarter) stood at 248.01% in 2019, then skyrocketed by 59bps to 102.73% in 2020, then crashed by -574bps to 692.44% in 2021, then crashed by -919bps to 7056.0% in 2022, then plummeted by -45bps to 10204.69% in 2023.
  • Its Net Margin was 10204.69% in Q4 2023, compared to 2206.13% in Q3 2023 and 36.81% in Q2 2023.